Soft tissue tumor refers to a type of cancer that occurs in soft tissues of the body such as tendons, lymph vessels, muscle, blood vessels, nerves, fat, and tissue covering joints.
Global Benign and Malignant Soft Tissue Tumors Treatment Market: Snapshot
In human anatomy, soft tissue aka supportive tissue surrounds various body organs. Soft tissue comprises adipose tissue, fibrous connective tissue, skeletal muscle, peripheral nervous system, and blood/lymph vessels.
Soft tissue tumor refers to a type of cancer that occurs in soft tissues of the body such as tendons, lymph vessels, muscle, blood vessels, nerves, fat, and tissue covering joints. Soft tissue tumors are primarily classified as malignant or benign, while the remaining are of intermediate nature. The prevalence of benign soft tissues is 10 times more than that of malignant ones. Soft tissue tumors could develop anywhere in the body, however, they develop more in legs, chest, and arms.
Almost 45% of soft tissue tumors develop in the lower extremities, 15% develop in upper extremities, 15% in retroperitoneum, 10% develop in the head and neck area, and the remnant 15% in the abdominal and chest wall.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35900
Soft tissue tumors affect adult and children like; however, the age adjusted prevalence of soft tissue tumors range from 15 years to 35 years for every 1 million population. Nevertheless, the incidence of soft tissue tumors increases with age and is comparatively higher in men than compared to women. People with gene mutation or genetic disorders are more susceptible to soft tissue tumors.
Benign soft tissue tumors are common and can be treated with surgery alone. Malignant soft tissue tumors, prior to 1970s, were treated with surgery and majority patients with high-grade tumors were poor receptors of the therapy resulting in significant mortality. Chemotherapy, radiation therapy, and advanced surgical techniques that have been used for malignant soft tissue tumors lately have increased survival rate and have reduced the need for ablative surgery.
Request for Analysis of COVID-19 Impact on Benign and Malignant Soft Tissue Tumors Treatment Market -https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=35900
Soft tissue is also known as supportive tissue surrounding various organs present in the body. It includes adipose tissue, blood vessels, fibrous connective tissue, lymph vessels, skeletal muscle, and the peripheral nervous system. Soft tissue tumor is a type of cancer that occurs in soft tissues of the body, including lymph vessels, tendons, muscle, fat, blood vessels, tissue covering joints, and nerves. Soft tissue tumors are classified into either benign or malignant, while the rest are of intermediate nature. Benign soft tissue tumors occur 10 times more frequently than malignant ones. Soft tissue tumors can occur anywhere in the body, but most often form in the legs, arms, or chest. Approximately 45% of soft tissue tumors occur in the lower extremities, 15% in the retroperitoneum, 15% in the upper extremities, 10% in the head-and-neck region, and the remaining 15% in the abdominal and chest wall. Both children and adults are equally affected; however, the age adjusted annual incidence of soft tissue tumors range from 15 years to 35 years per 1 million population. The incidence increases steadily with age and is slightly higher in men compared to women. People with genetic disorders or gene mutation are at higher risk of developing soft tissue tumors.
Pre book Benign and Malignant Soft Tissue Tumors Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=35900<ype=S
The global benign and malignant soft tissue tumors treatment market can be segmented based on treatment type, end-user, and region. In terms of treatment type, the market can be categorized into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy, and surgery. Chemotherapy treatment generally involves a combination of various anti-neoplastic agents. The commonly used drugs include ifosfamide and doxorubicin. The other chemotherapeutics agents include dacarbazine, paclitaxel, cisplatin, eribulin, oxaliplatin, and vincristine. Chemotherapy and targeted therapy are anticipated to dominate the benign and malignant soft tissue tumors treatment market during the forecast period. Based on end-user, the global benign and malignant soft tissue tumors treatment market can be classified into hospitals, ambulatory surgical centers, and others. Multi-specialty hospitals are anticipated to gain the highest market share during the forecast period. Rise in incidence and prevalence of soft tissue tumor, increased research and development expenditure, significant pipeline of drugs, growing awareness among people are the factors that contribute to the growth of the market. However, high cost of treatment and side effects associated with it, disappointing results of promising pipeline molecules, and stringent government regulations are likely to hamper the market.
Read More Information: https://www.transparencymarketresearch.com/benign-malignant-soft-tissue-tumors-treatment-market.html
Geographically, the global benign and malignant soft tissue tumors treatment market can be segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate that global market, followed by Europe. High incidence of soft tissue tumors, growing awareness among people, increased research and development expenditure, and well-established health care infrastructure contribute to the growth of the market. The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period, driven increased government initiatives and developing health care infrastructure in India and China. The market in Latin America and Middle East & Africa is anticipated to grow during the forecast period, owing to increase in investments by market players in these regions and rise in prevalence of soft tissue tumors.
Leading players in the global benign and malignant soft tissue tumors treatment market include Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Inc. Teva Pharmaceuticals, GlaxoSmithKline, and Celgene Corporation.
Browse More Trending Reports by Transparency Market Research:
Alpha 1 Antitrypsin Deficiency Treatment Market :
As per the latest professional survey report on the global alpha 1 antitrypsin deficiency treatment market by the Transparency Market Research, the industry is anticipated to rise at a significant growth rate of 10.1 % over the forecast period, i.e. 2019 to 2027. Furthermore, the research report also states that the global alpha 1 antitrypsin deficiency treatment market was evaluated at US$ 1.4 billion in the year 2018. Some of the major driving factors that are supplementing the demand in the global alpha 1 antitrypsin deficiency treatment market are increasing prevalence as well as high incidence of various respiratory diseases and increasing awareness amongst public about AAT deficiency and its treatment options.
Automated External Defibrillators Market :
Automated external defibrillator is gaining impetus owing to its ability to assist in restoring irregularities in heart rhythm using technique of giving electric shock to the heart. These devices are intended for the identification and treatment of two types of nonstandard heart rhythms such as ventricular fibrillation (VF) and pulseless ventricular tachycardia (pulseless VT). Rise in the utilization of this device in the treatment of patients with abrupt cardiac arrest is estimated to create revenue-generation opportunities in the global automated external defibrillators market in the years ahead. Furthermore, surge in number of people addicted to alcohol and smoking may bring lucrative prospects in the market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453